Creating a new RNA treatment for ovarian cancer
Development of a DISE-inducing, short RNA therapeutic to treat ovarian cancer
This study is testing a new RNA-based treatment for ovarian cancer that helps kill cancer cells while being gentle on healthy tissues, aiming to improve your quality of life and potentially cure or manage the cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nuago Therapeutics INC NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11065199 on NIH RePORTER |
What this research studies
This research focuses on developing a novel RNA-based therapy aimed at treating ovarian cancer by inducing a specific type of cell death that cancer cells cannot resist. The approach utilizes short interfering RNAs (sRNAs) that target multiple survival genes in cancer cells, effectively silencing them and preventing the cancer from growing. The therapy is designed to be safe for normal tissues, minimizing side effects and improving the quality of life for patients. The goal is to provide a treatment that can either cure the cancer or manage it as a chronic condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian cancer who have not responded well to existing treatments.
Not a fit: Patients with non-cancerous conditions or those with cancers that are not ovarian may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment for ovarian cancer that is effective and has fewer side effects than current therapies.
How similar studies have performed: This approach is based on innovative research that has shown promise in targeting cancer cells effectively, suggesting potential for success in this novel application.
Where this research is happening
Chicago, United States
- Nuago Therapeutics INC — Chicago, United States (Active)
Researchers
- Principal investigator: Schickel, Robert — Nuago Therapeutics INC
- Study coordinator: Schickel, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.